[go: up one dir, main page]

WO2014083575A2 - Improved process for the preparation of boceprevir intermediate - Google Patents

Improved process for the preparation of boceprevir intermediate Download PDF

Info

Publication number
WO2014083575A2
WO2014083575A2 PCT/IN2013/000697 IN2013000697W WO2014083575A2 WO 2014083575 A2 WO2014083575 A2 WO 2014083575A2 IN 2013000697 W IN2013000697 W IN 2013000697W WO 2014083575 A2 WO2014083575 A2 WO 2014083575A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
process according
acid
give
Prior art date
Application number
PCT/IN2013/000697
Other languages
French (fr)
Other versions
WO2014083575A3 (en
Inventor
Shankar Rama
Sarat Chandra Srikanth Gorantla
Raja Reddy ANUPATI
Hima Prasad Naidu
Suresh Reddy SABBELLA
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Publication of WO2014083575A2 publication Critical patent/WO2014083575A2/en
Publication of WO2014083575A3 publication Critical patent/WO2014083575A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04Formation of amino groups in compounds containing carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/12Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring

Definitions

  • the present invention relates to the process for the preparation of 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof and its further conversion into Boceprevir.
  • Boceprevir (lR,5S)-N-[3-Amino-l-(cyclobutyImethyI)-2,3-dioxopropyl]-3-[2(S)- [[[(l,l-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-l-oxobutyl]-6,6-dimethyl-3- azabicyclo [3.1.0]hexan-2(S)-carboxamide, having formula I is a hepatitis C virus ("HCV”) protease inhibitor, developed by Merck & Co and marketed under the brand name of VICTRELIS.
  • HCV hepatitis C virus
  • the processes exemplified above employ hazardous reagents and are difficult to handle in an industrial scale. There is a need in the art to provide a process which is not hazardous, cost effective with enhanced purity and yields.
  • the present invention provides a commercially viable and easy to handle process with simple reagents and with enhanced purity and yield of intermediate I or an acid addition salt thereof.
  • the principle object of the present invention is to provide an improved process for preparing 3-amino-3-cyclobutylmethyl-2-hydroxypropiffnide of Intermediate I or an acid addition salt thereof.
  • Another object of the present inv e a novel intermediate of formula E.
  • the present invention provides a process for preparing 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide of Intermediate I or an acid addition salt thereof comprising the steps of:
  • the present invention provides an improved process for preparing 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof of Intermediate I. It also provides a novel intermediate of formula E.
  • R- alkyl group L-Leaving group ; P-Protecting group
  • R- refers to an alkyl group straight or branched CI -9 alkyl, includes methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, s-butyl, t-butyl.
  • L refers to a leaving groups known in the art includes, halides, sulphoriate groups such as alkylsulphonates arylsulphonates.
  • P refers a protecting group known in the art includes Di t-Butyl dicarbamate (Boc), Benzyl carbamate, acetamide, trifluoroacetamide, phthalimide, benzylchloride, benzoylchloride, tritylamine, bertzylideneamine, tosylamide, methoxyethxoxymethyl, tetrahydropyaranyl (THP), and tertiary butyl.
  • Di t-Butyl dicarbamate Boc
  • Benzyl carbamate Benzyl carbamate
  • acetamide trifluoroacetamide
  • phthalimide benzylchloride
  • benzoylchloride benzoylchloride
  • tritylamine bertzylideneamine
  • tosylamide methoxyethxoxymethyl
  • THP tetrahydropyaranyl
  • Halide refers to F, CI, Br and I.
  • the present invention provides a process for preparing 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof of Intermediate I comp ising the steps of: a) A with compound of
  • R- alkyl group L-Leaving group; P-Protecting group.
  • a benzophenone imine compound of formula A is reacted with cyclobutyl methyl derivative of formula B to give amine compound of formula C in the presence of a suitable base and solvent.
  • the suitable base is selected from metal hydroxide includes potassium hydroxide (KOH), sodium hydroxide (NaOH), metal carbonate includes sodium carbonate and potassium carbonate, preferably metal hydroxide potassium hydroxide;
  • the suitable solvent is selected from polar aprotic solvent such as dimethyl sulfoxide ⁇ (DMSO), dimethylacetamide, tetrahydrofuran (THF), acetone, dimethyl formamide (DMF) and acetonitrile; preferably DMSO.
  • DMSO dimethyl sulfoxide ⁇
  • THF tetrahydrofuran
  • acetone dimethyl formamide
  • acetonitrile preferably DMSO.
  • the reaction between compound of formula A and cyclobutyl methyl derivative of formula B can optionally be carried out in presence of a phase transfer catalyst such as tetrabutyl ammonium bromide (TBAB) and crown ethers to give amine compound of formula C.
  • TBAB tetrabuty
  • the amine compound of formula C is protected with protecting group P by treating with a protecting agent in a suitable solvent includes hexane, diethyl ether and methylene chloride (MDC), preferably methylene chloride.
  • a protecting agent in a suitable solvent includes hexane, diethyl ether and methylene chloride (MDC), preferably methylene chloride.
  • MDC methylene chloride
  • the amine protected compound of formula C is hydrolysed to obtain formula D by treating with a base and suitable solvent, wherein the suitable base is selected from alkaline metal hydroxide, preferably NaOH in a suitable solvent selected from polar solvents such as methanol, ethanol, isopropyl alcohol (IP A) and propanol, arid butanol, preferably ethanol.
  • the acid compound of formula D is converted into a morpholine amide of formula E by treating formula D with a morpholine in presence of a suitable solvent and coupling agent.
  • the suitable solvent includes methylene chloride (MDC), toluene, xylene and carbon tetrachloride (CC1 4 ), preferably methylene chloride.
  • the suitable coupling agent includes l-ethyl-3-(3-dimethylaminopropyl)carbodiimide) hydrochloride (EDC.HC1), ⁇ , ⁇ '-Dicyclohexylcarbodiimide (DCC), 1,1 * - Carbonyldiimidazole (CDI).
  • EDC.HC1 l-ethyl-3-(3-dimethylaminopropyl)carbodiimide) hydrochloride
  • DCC ⁇ , ⁇ '-Dicyclohexylcarbodiimide
  • CDI 1,1 * - Carbonyldiimidazole
  • Compound of formula E can also be prepared by reacting alkylchloroformates such as ethylchloroformate, isobutylchloroformate with a compound of formula D followed by a morpholine.
  • compound of formula E can also be prepared directly from amino protected compound of formula C by reacting with a morpholine.
  • formula E is also prepared by converting
  • the morpholine amide compound of formula E is reduced into aldehyde compound of formula F by treating formula E with suitable reducing agent and suitable solvent, wherein the suitable reducing agent includes lithium aluminium hydride (LAH), diisobutylaluminum hydride (DIBAL-H) and sodium bis(2-methoxyethoxy) aluminumhydride (vitride).
  • suitable reducing agent includes lithium aluminium hydride (LAH), diisobutylaluminum hydride (DIBAL-H) and sodium bis(2-methoxyethoxy) aluminumhydride (vitride).
  • the suitable solvent includes ether solvents such as toluene, tetrahydrofuran (THF), diethyl ether.
  • the present invention provides a novel and simple process by replacing compound of formula J with the morpholine amide of formula E and further it is successfully established the reduction of compound of Formula J into corresponding aldehyde in process of preparing Intermediate I by employing commercially feasible reagent such as vitride solution instead of hazardous metallic hydride such as Lithium aluminium hydride.
  • the aldehyde compound of formula F is reacted with a cyanohydrin compound in presence of a suitable base and suitable solvent such as toluene, dichloromethane to obtain cyano compound of formula G.
  • the cyanohydrin compound for the reaction is selected from ketone cyanohydrin, preferably acetone cyanohydrin.
  • the base is selected from diisopropyl ethyl amine, dimethylamine, triethyl amine (TEA), trirnethyl amine, methylamine, ethanolamme, triphenylamine, pyridine and piperidine, preferably TEA.
  • the cyanohydrin compound of formula G is hydrolyzed with a base in a suitable solvent such as DMSO and in presence H 2 0 2 to obtain amide compound of formula H, wherein the base is selected from potassium carbonate, sodium carbonate, preferably potassium carbonate.
  • the cyanohydrin compound of formula G is converted into Intermediate I of ah acid addition salt thereof as per the process disclosed in US 20050249702 depicted in scheme 3,
  • the amide compound of formula H is deprotected by treating with an acid in suitable solvent to give Intermediate I or an acid addition salt thereof
  • the acid is selected from hydrochloric acid (HQ), hydrobromic acid (HBr), sulfuric acid (H 2 S04), trifluoro acetic acid (TFA), phosphoric acid (H 3 PO 4 ), paratoluene sulfonic acid (pTSA) and the like, preferably HCl.
  • the suitable solvent is selected from polar solvents such as methanol, ethanol, n-propanol, isopropyl alcohol (IPA) and butanol preferably IPA.
  • present invention provides an improved process for preparing an aldehyde compound of formula F by reducing compound of formula J as represented in scheme 5.
  • the reduction of the compound of formula J into compound of formula F is carried out by treating compound of formula J with sodium bis(2-methoxyethoxy)alumirtumhydride (Vitride) in a suitable solvent selected from polar aprotic solvent includes, tetrahydrofurari (THF); preferably THF.
  • a suitable solvent selected from polar aprotic solvent includes, tetrahydrofurari (THF); preferably THF.
  • the present invention provides novel intermediate of formula E.
  • the novel morphoiine compound of formula E is converted into Boceprevir of formula I.
  • the aldehyde compound of formula J is further converted into Boceprevir by the conventional methods.
  • the Intermediate I is converted into Boceprevir of formula I as per the process disclosed in US 7012066, US 20050249702, WO 2008079216 and WO2002008244.
  • N-diphenylmethyleneglycine ethyl ester (17.9 g, Example 1) was dissolved in 50 ml of DMSO and cooled to 0 °C. To this 11.27 g of potassium hydroxide was added and stirred for 10 min. To the reaction mixture 10 g of Cyclobutyl methyl bromide (Formula B-Leaving group is halide, preferably Br) was added at 0 °C and continued stirring for one hour at 0 °C. After completion of the reaction, toluene was added to the reaction mass and filtered through Hyflo bed. Water was added to the filtrate and extracted with toluene.
  • Formula B-Leaving group is halide, preferably Br

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the process for the preparation of 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof and its further conversion into Boceprevir.

Description

IMPROVED PROCESS FOR THE PREPARATION OF BOCEPREVIR INTERMEDIATE
FIELD OF INVENTION
The present invention relates to the process for the preparation of 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof and its further conversion into Boceprevir. BACKGROUND OF THE INVENTION
Boceprevir, (lR,5S)-N-[3-Amino-l-(cyclobutyImethyI)-2,3-dioxopropyl]-3-[2(S)- [[[(l,l-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-l-oxobutyl]-6,6-dimethyl-3- azabicyclo [3.1.0]hexan-2(S)-carboxamide, having formula I is a hepatitis C virus ("HCV") protease inhibitor, developed by Merck & Co and marketed under the brand name of VICTRELIS.
Figure imgf000002_0001
Inter mediate I US patent 6992220 claims a process for the synthesis of Intermediate I and is represented in below scheme 1.
Figure imgf000003_0001
VII
VI
Figure imgf000003_0002
Scheme 1
VIII
US 2011034705 disclose that the process described in US 6992220 ends with low yield of Intermediate I from the various intermediates described therein.
US 201 1034705 describe a process for preparing Intermediate I and is represented as shown in Scheme 2.
Figure imgf000004_0001
ij The processes exemplified above employ hazardous reagents and are difficult to handle in an industrial scale. There is a need in the art to provide a process which is not hazardous, cost effective with enhanced purity and yields. The present invention provides a commercially viable and easy to handle process with simple reagents and with enhanced purity and yield of intermediate I or an acid addition salt thereof.
OBJECT AND SUMMARY OF THE INVENTION
The principle object of the present invention is to provide an improved process for preparing 3-amino-3-cyclobutylmethyl-2-hydroxypropionarnide of Intermediate I or an acid addition salt thereof. Another object of the present inv e a novel intermediate of formula E.
Figure imgf000005_0001
Formula E
P- Amiiie protecting group.
In one aspect, the present invention provides a process for preparing 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide of Intermediate I or an acid addition salt thereof comprising the steps of:
a) reacting a benzophenone imine compound of formula A with a compound of formula B to give a compound of formula C,
Figure imgf000005_0002
Formula A Formnla B
Formula C
- alk l group ; L-Leaving group ; b) protecting and hydrolyzing the compound of formula C to give compound of formula D,
Figure imgf000006_0001
Formula C Formula D
P-P btectin group
c) reacting compound of formula D with a morpholihe to give compound of formula
Figure imgf000006_0002
Formula D
Formula E
d) E to give compound of formula F,
Figure imgf000006_0003
Formula F
e) reacting compound of formula F with a cyanohydrin compound to give compound of formula G,
f) ound of forrnula H , and
Figure imgf000006_0004
g) deprotecting compound of formula H and optionally isolating Intermediate I as its acid addition salt.
Figure imgf000007_0001
Formula H Intermediate I In another aspect, the Iriterniediate I is converted into Bbceprevir of formula I.
DETAILED DESCRIPTION 0F THE INVENTION:
The present invention provides an improved process for preparing 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof of Intermediate I. It also provides a novel intermediate of formula E.
The schematic representation of "the present iriyention has given in scheme 4.
Figure imgf000007_0002
Formula C Formula D
Figure imgf000007_0003
Formula G
Formula E Formula F
Figure imgf000007_0004
Formula H Intermediate I
R- alkyl group ; L-Leaving group ; P-Protecting group
Scheitfe As used herein, R- refers to an alkyl group straight or branched CI -9 alkyl, includes methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, s-butyl, t-butyl.
L refers to a leaving groups known in the art includes, halides, sulphoriate groups such as alkylsulphonates arylsulphonates.
P refers a protecting group known in the art includes Di t-Butyl dicarbamate (Boc), Benzyl carbamate, acetamide, trifluoroacetamide, phthalimide, benzylchloride, benzoylchloride, tritylamine, bertzylideneamine, tosylamide, methoxyethxoxymethyl, tetrahydropyaranyl (THP), and tertiary butyl.
Halide refers to F, CI, Br and I.
In one aspect, the present invention provides a process for preparing 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof of Intermediate I comp ising the steps of: a) A with compound of
b) to give a compound of
Figure imgf000008_0001
P-Protecting group reacting the compound of formula D with a morpholine to give a compound of formula E,
ompound of formula F,
yanohydri compound to give a
Figure imgf000009_0001
Formula G
Formula F
f) hydrolyzing compound of formula G to give compound of formula H,
Figure imgf000009_0002
Formula G
Formula H arid
g) deprotecting the compound of formula H arid optionally isolating Intermediate I as its acid addition salt
Figure imgf000009_0003
Formula H Intermediate I
R- alkyl group; L-Leaving group; P-Protecting group. In one embodiment, a benzophenone imine compound of formula A is reacted with cyclobutyl methyl derivative of formula B to give amine compound of formula C in the presence of a suitable base and solvent. The suitable base is selected from metal hydroxide includes potassium hydroxide (KOH), sodium hydroxide (NaOH), metal carbonate includes sodium carbonate and potassium carbonate, preferably metal hydroxide potassium hydroxide; the suitable solvent is selected from polar aprotic solvent such as dimethyl sulfoxide ^ (DMSO), dimethylacetamide, tetrahydrofuran (THF), acetone, dimethyl formamide (DMF) and acetonitrile; preferably DMSO. The reaction between compound of formula A and cyclobutyl methyl derivative of formula B can optionally be carried out in presence of a phase transfer catalyst such as tetrabutyl ammonium bromide (TBAB) and crown ethers to give amine compound of formula C.
In US 6992220 and US 20050249702, the reaction of a benzophenone imine compound of formula A with cyclobutyl methyl halide of formula B is carried out in presence of potassium tertiary butoxide, wherein in the present invention said reaction is performed in presence of alkaline metal hydroxide such as KOH which results into cost effective and less time cycled.
In another embodiment, the amine compound of formula C is protected with protecting group P by treating with a protecting agent in a suitable solvent includes hexane, diethyl ether and methylene chloride (MDC), preferably methylene chloride. The protection can be carried out by following the procedures as described in Theodora W. Greene and Peter G. M. Wuts, "Protecting Groups In Organic Synthesis," third edition, John Wiley and Sons, New York. N.Y.
In another embodiment, the amine protected compound of formula C is hydrolysed to obtain formula D by treating with a base and suitable solvent, wherein the suitable base is selected from alkaline metal hydroxide, preferably NaOH in a suitable solvent selected from polar solvents such as methanol, ethanol, isopropyl alcohol (IP A) and propanol, arid butanol, preferably ethanol. In one more embodiment, the acid compound of formula D is converted into a morpholine amide of formula E by treating formula D with a morpholine in presence of a suitable solvent and coupling agent. The suitable solvent includes methylene chloride (MDC), toluene, xylene and carbon tetrachloride (CC14), preferably methylene chloride. The suitable coupling agent includes l-ethyl-3-(3-dimethylaminopropyl)carbodiimide) hydrochloride (EDC.HC1), Ν,Ν'-Dicyclohexylcarbodiimide (DCC), 1,1*- Carbonyldiimidazole (CDI). The said reaction is optionally carried out in presence of an activator like 1-hydroxybenzotraizole. Compound of formula E can also be prepared by reacting alkylchloroformates such as ethylchloroformate, isobutylchloroformate with a compound of formula D followed by a morpholine. Alternatively compound of formula E can also be prepared directly from amino protected compound of formula C by reacting with a morpholine. In another embodiment of the present invention, formula E is also prepared by converting
Figure imgf000011_0001
In another embodiment, the morpholine amide compound of formula E is reduced into aldehyde compound of formula F by treating formula E with suitable reducing agent and suitable solvent, wherein the suitable reducing agent includes lithium aluminium hydride (LAH), diisobutylaluminum hydride (DIBAL-H) and sodium bis(2-methoxyethoxy) aluminumhydride (vitride). The suitable solvent includes ether solvents such as toluene, tetrahydrofuran (THF), diethyl ether.
In comparison with the prior art processes, the present invention provides a novel and simple process by replacing compound of formula J with the morpholine amide of formula E and further it is successfully established the reduction of compound of Formula J into corresponding aldehyde in process of preparing Intermediate I by employing commercially feasible reagent such as vitride solution instead of hazardous metallic hydride such as Lithium aluminium hydride. In one more embodiment, the aldehyde compound of formula F is reacted with a cyanohydrin compound in presence of a suitable base and suitable solvent such as toluene, dichloromethane to obtain cyano compound of formula G. The cyanohydrin compound for the reaction is selected from ketone cyanohydrin, preferably acetone cyanohydrin. The base is selected from diisopropyl ethyl amine, dimethylamine, triethyl amine (TEA), trirnethyl amine, methylamine, ethanolamme, triphenylamine, pyridine and piperidine, preferably TEA. Yet in another embodiment, the cyanohydrin compound of formula G is hydrolyzed with a base in a suitable solvent such as DMSO and in presence H202 to obtain amide compound of formula H, wherein the base is selected from potassium carbonate, sodium carbonate, preferably potassium carbonate. In one embodiment, the cyanohydrin compound of formula G is converted into Intermediate I of ah acid addition salt thereof as per the process disclosed in US 20050249702 depicted in scheme 3,
In one embodiment, the amide compound of formula H is deprotected by treating with an acid in suitable solvent to give Intermediate I or an acid addition salt thereof The acid is selected from hydrochloric acid (HQ), hydrobromic acid (HBr), sulfuric acid (H2S04), trifluoro acetic acid (TFA), phosphoric acid (H3PO4), paratoluene sulfonic acid (pTSA) and the like, preferably HCl. The suitable solvent is selected from polar solvents such as methanol, ethanol, n-propanol, isopropyl alcohol (IPA) and butanol preferably IPA.
Yet another embodiment, the amide compound of formula H is converted into Intermediate I by the conventional methods.
In another aspect, present invention provides an improved process for preparing an aldehyde compound of formula F by reducing compound of formula J as represented in scheme 5.
Figure imgf000013_0001
Formula J
Figure imgf000013_0002
compound of formula J into aldehyde compound of formula F by substituting hazardous reducing agents like LAH with vitride solution to offer a commercially viable process.
According to the present invention, the reduction of the compound of formula J into compound of formula F is carried out by treating compound of formula J with sodium bis(2-methoxyethoxy)alumirtumhydride (Vitride) in a suitable solvent selected from polar aprotic solvent includes, tetrahydrofurari (THF); preferably THF.
In another aspect, the present invention provides novel intermediate of formula E.
Figure imgf000013_0003
Formula E
P- Amide protecting group. In one embodiment, the novel morphoiine compound of formula E is converted into Boceprevir of formula I.
In one more embodiment, the aldehyde compound of formula J is further converted into Boceprevir by the conventional methods. in another embodiment, the Intermediate I is converted into Boceprevir of formula I as per the process disclosed in US 7012066, US 20050249702, WO 2008079216 and WO2002008244.
The following non-limiting examples illustrate specific embodiments of the present invention. The examples are not intended to be limiting the scope of present inventio in any way.
Examples:
Example -1: Synthesis of Benzophenone imine
Figure imgf000014_0001
129.8 g of Benzophenone, 50 g of glycine ethyl ester hydrochloride (0.5 moles), 3.38 g of 7-t0luenestilf0nic acid (0.05 moles) and 205 ml toluene were taken in to BF equipped with dean-stark apparatus. To the reaction mixture was added 96.59 g of N,N- diisopropyl ethyl amine and was heated to 1 10-1 19 °C and maintained at same temperature with stirring for six hours. During the reaction, water was removed from the reaction azeotropically. After completion of the reaction, the reaction mixture was cooled to 20 °C and the reaction- mixture was washed with water and layers were separated. The organic layer was concentrated under reduced pressure to get the product as an oily residue (169 g).
Example -2: Preparation of formula C (R = ethyl)
Figure imgf000014_0002
(N-diphenylmethylene)glycine ethyl ester (17.9 g, Example 1) was dissolved in 50 ml of DMSO and cooled to 0 °C. To this 11.27 g of potassium hydroxide was added and stirred for 10 min. To the reaction mixture 10 g of Cyclobutyl methyl bromide (Formula B-Leaving group is halide, preferably Br) was added at 0 °C and continued stirring for one hour at 0 °C. After completion of the reaction, toluene was added to the reaction mass and filtered through Hyflo bed. Water was added to the filtrate and extracted with toluene. The organic layers were combined and washed with brine solution; dried over anhydrous Na2S04 and concentrated under reduced pressure to get oily residue. The resulting oily residue was dissolved in diisopropyl ether and added 50% aqueous HCl solution. The reaction mass was maintained at room temperature with stirring for 3 hours. Separated the aqueous layer from reaction mass and neutralized with aqueous sodium carbonate solution. Extracted the product with dichloromethane and concentrated under reduced pressure to get product as an oily mass (7 g). Example-3: Pre
Figure imgf000015_0001
Formula C Formula D
To a solution of amine (7 g, Example-2) in 70 ml of dichloromethane, 9.39 g of ditert-butyl dicarbonate was added at 0 °C. The reaction mixture was stirred for 12 hrs at room temperature. After completion of the reaction, reaction mixture was concentrated under reduced pressure to get an oily residue. The oily residue was dissolved in 10 ml of rnethanol/ethanol and treated with sodium hydroxide solution (3g in 20 ml of water) and stirred for 3 hrs at room temperature. After completion of reaction, reaction mass was concentrated under reduced pressure and water was added and stirred for 10 min. The reaction mixture was cooled to 10-15 °C and pH was adjusted to 1-2 by using IN HCl solution. The product was extracted with dichloromethane. The combined organic layers were dried over Na S04 and concentrated under reduced pressure to get the product as an oily mass (8 g). Example-4: Preparation of formula E (P
Figure imgf000016_0001
Formula D Formula E
To a solution of BOC-acid (8 g, example-3) in 80 ml of dichloromethane, 5.18 g of 1-Hydroxybenzotraizole and 10 ml of morpholine were added under nitrogen atmosphere. To the above reaction mixture 7.56 g of l-ethyl-3-(3- dimethylaminopropyl)carbodiimide) hydrochloride (EDC.HCl) was added and stirred for 4 hrs. After completion of reaction, reaction mixture was filtered and washed with dichloromethane. The filtrate was washed with 10% aqueous HC1 solution and separated the organic layer. The organic layer was washed with 5% sodium bicarbonate solution followed by brine solution. The organic layer was dried over Na2S04 and concentrated under reduced pressure to obtain 6 g product as solid.
Example-5: Preparation of formula E (P = Boc):
Pivaloyl chloride
Figure imgf000016_0002
To a solution of BOC-acid (10 g, example-3) in 100 ml of dichloromethane was added Triethylamine (13.74 gm) at -15 °C. Then added 5.95 gm of Pivaloyl chloride and stirred for one hour at -15 °C under nitrogen atmosphere. 4.47 gm of Morpholine was added to the above reaction mass at -15 °C and stirred for one hour. After completion of reaction, water was added and separated the layers. Organic layer washed with 10% aqueous HC1 solution followed by 5% Sodium bicarbonate solution. Finally washed the organic layer with brine solution and dried over Na2S0 . Concentrated the organic layer under reduced pressure and recrystallized using hexane/heptane to get 11 gm product as white solid. Example -6: Preparation of formula F (P
Figure imgf000017_0001
to get the product as an oily mass (2.4 g).
Exampie-7:
Figure imgf000017_0002
Formula J
To a solution of 5 g of BOC-acid (Example-3) in 100 ml of dichloromethane, 3.3 g of l-HydrOxybenzotraizole, 9.1 1 ml of diisopropyl ethyl amine and 3 g of Ν,Ο- dimethylhydroxylamine hydrochloride were added under nitrogen atmosphere. To the reaction mixture 4.72 g of EDC.HC1 was added and stirred for 12 hrs. After completion of reaction, 100 ml of 20% aqueous HC1 solution was added, stirred and the layers were separated. Aqueous layer was extracted with dichloromethane and the organic layers were combined arid were washed with saturated sodium bicarbonate solution, followed by brine solution. The organic layer was dried over Na2SG4 and concentrated under reduced pressure to get 5 g of product as white solid. Example-8: Preparation of formula F (P
Figure imgf000018_0001
Formula J
2 g of solution of compound of formula J (Example-6) in 20 ml of tetrahydrofuran was cooled to 0 °C and vitride solution (6.05 ml, 70% solution in toluene) was added drop wise. The reaction mixture was slowly heated to room temperature and stirred for 3 hours. After completio of. reaction, the reaction mixture was cooled to 0-5 °C and quenched with ice water followed by 10% aqueous HCI solution. Then, to the reaction mixture dichlGroniethane was added and filtered through hyflow bed and Washed with dichloromethane. The layers were separated and aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine solution, dried over Na2S04 and concentrated under reduced pressure to get the product as an oily mass (1.5 g). Exampl-9: Preparation of formula G (P = Boc)
Figure imgf000018_0002
Formula G
Formula F
To the 1 g solution of BOC-aldehyde (formula F- P is Boc) in 10 ml of toluene 1.5 g of acetone cyanohydrin and triethylamine (1.22 ml) were added and stirred for 24 h at room temperature. After completion of the reaction, 20 ml of 10% aqueous HCI solution were added and stirred. The layers were separated and the aqueous layer was extracted with toluene and organic layers Were combined. The combined organic layers were washed with water followed by brine solution, dried over Na2S0 and concentrated under reduced pressure to get the product as an oily mass (1 g). Example-10: Preparation of formula H (P
Figure imgf000019_0001
Formula G Formul H
To the 1 g solution of BOC-cyano alcohol (Example-8) in 5 ml of DMSO 0.5 g of potassium carbonate was added and heated to 40-45 °C. To the reaction mixture 2 ml of 35% H202 solution was added drop wise over one hour and stirred at same temperature for 4 h. After completion of the reaction 15 ml of water was added and cooled to 0 °C and continued stirring for 5 h at same temperature. The reaction mixture was filtered. The obtained solid was washed with water and dried at 50-55 °C for 6 h give 0.4 g of product.
Example 11: Preparation of Intermediate I.
Figure imgf000019_0002
Formula H Intermediate I
To the 0.5 g solution of BOC-hydroxy amide (Example-9) in 3 ml isopropyl alcohol IPA.HC1 solution (2 mi, 9% w/w) was added. The reaction mass temperature was heated to 40-45 °C and continued stirring for 6 hours. The reaction mass temperature was cooled to 0-5 .°C and stirred for one hour. Filtered the obtained solid and dried at '■ 6.0-65 °C for 6 hours to give 0.3 g of compound.

Claims

Claims:
1. A process for preparing intermediate compound of formula I comprising the steps of :
Figure imgf000020_0001
Intermediate I
a) reducin a com ound of formula E to give a compound of formula F,
Figure imgf000020_0002
Formula E Formula F
b) reacting the compound of formula F with a cyanohydrin compound to give a compound of formula G,
Figure imgf000020_0003
Formula G
Formula F
c) e a compound of formula H,
Figure imgf000020_0004
Foula G ' Formula H and
d) deprotecting the compound of formula H and optionally isolating Intermediate
Figure imgf000020_0005
Formula H Intermediate I
R- alkyl group; L-Leaving group; P-Protecting group.
2. The process according to the claim 1, wherein the reducing step is carried out with a reducing agent selected from lithium aluminium hydride (LAH), diisohutylalurninum hydride (DIBAL-H) and sodium bis(2-methoxyethoxy) aluminumhydride (vitride).
3. TM'- ri>cesg ',aei¾idftig to the claim 1, wherein the compound of formula F is reacted with cyanohydrin in presence of a base arid a solvent.
4. The process according to the claim 3, wherein the suitable base is selected from diisopropyl ethyl amine, dimethylamine, triethyl amine (TEA), trimethyl amine, methylamine, ethanolarriine, triphenylamine, pyridine and piperidine and the like.
5. The process according to the claim 1, wherein the compound of formula G is hydro lyzed in presence of a base.
6. The process according to the claim 5, wherein the base is selected from potassium carbonate, sodiurh carbonate arid the like.
7. The process according to the claim 1, wherein the compound of formula H is optionally deprotected by treating with an acid arid a suitable solvent.
8. The process according to the claim 7, wherein the suitable acid is selected from hydrochloric acid HC1), hydrobrOrnic acid (HBr), sulfuric acid (H S04), trifluoro acetic acid (TFA), phosphoric acid (H3P04), paratoluene sulfonic acid (pTSA) and the like.
9. The process according to the claim 1 , wherein the compound of formula E is prepared comprising the steps of : a) reacting a benzophenone imine compound of formula A with compound of formula B to give compound of formula C,
Figure imgf000022_0001
Formula A Formula B
Formula C
R- alkyl group ; L-Leaving group ;
b) protecting and hydrolyzing the compound of formula C to give a compound of formula D,
Figure imgf000022_0002
Formula C Formula D
P-Protecting group
c) reacting the compound of formula D with a morpholine to give the compound of formula E,
Figure imgf000022_0003
Formula D
Formula E
P-Protecting group
10. A process for preparing compound of formula F comprising reducing formula J with sodium bis(2-methoxyethoxy)aluminumhydride (Vitride) in a suitable solvent.
Figure imgf000022_0004
Formula F
Formula J
R- alkyl group; P-protecxtlng group
11. The process according to the claim 10, wherein the suitable solvent is tetrahydfofuran.
12. A Compound of formula E.
Figure imgf000023_0001
Formula E
P-Protecting group
13. The use of compound of claim 12, in the preparation of Intermediate I.
14. The use of compound of claim 12, in the preparation of Boceprevir.
15. The process according to the proceeding claims, wherein the compound of formula I is further converted into Boceprevir.
PCT/IN2013/000697 2012-11-29 2013-11-14 Improved process for the preparation of boceprevir intermediate WO2014083575A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4980/CHE/2012 2012-11-29
IN4980CH2012 2012-11-29

Publications (2)

Publication Number Publication Date
WO2014083575A2 true WO2014083575A2 (en) 2014-06-05
WO2014083575A3 WO2014083575A3 (en) 2016-06-02

Family

ID=49956289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000697 WO2014083575A2 (en) 2012-11-29 2013-11-14 Improved process for the preparation of boceprevir intermediate

Country Status (1)

Country Link
WO (1) WO2014083575A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104744291A (en) * 2015-02-13 2015-07-01 宁波九胜创新医药科技有限公司 N-benzyl-4-cyclobutyl-2-hydroxy-3-nitrobutyrylamide and use thereof
CN112094204A (en) * 2019-06-18 2020-12-18 成都郑源生化科技有限公司 Method for preparing Fmoc-Tyr (tBu) -OH

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008244A2 (en) 2000-07-21 2002-01-31 Schering Corporation Peptides as ns3-serine protease inhibitors of hepatitis c virus
US20050249702A1 (en) 2004-05-06 2005-11-10 Schering Corporation (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
US6992220B2 (en) 2003-06-17 2006-01-31 Schering Corporation Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof
WO2008079216A1 (en) 2006-12-20 2008-07-03 Schering Corporation Process for preparing (1r,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
US20110034705A1 (en) 2007-12-21 2011-02-10 Schering-Plough Corporation Process For the Synthesis of 3- Amino-3-Cyclobuthylmethyl-2-Hydroxypropionamide or Salts Thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008244A2 (en) 2000-07-21 2002-01-31 Schering Corporation Peptides as ns3-serine protease inhibitors of hepatitis c virus
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US6992220B2 (en) 2003-06-17 2006-01-31 Schering Corporation Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof
US20050249702A1 (en) 2004-05-06 2005-11-10 Schering Corporation (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
WO2008079216A1 (en) 2006-12-20 2008-07-03 Schering Corporation Process for preparing (1r,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
US20110034705A1 (en) 2007-12-21 2011-02-10 Schering-Plough Corporation Process For the Synthesis of 3- Amino-3-Cyclobuthylmethyl-2-Hydroxypropionamide or Salts Thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THEODORA W. GREENE; PETER G. M. WUTS: "Protecting Groups In Organic Synthesis", JOHN WILEY AND SONS

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104744291A (en) * 2015-02-13 2015-07-01 宁波九胜创新医药科技有限公司 N-benzyl-4-cyclobutyl-2-hydroxy-3-nitrobutyrylamide and use thereof
CN112094204A (en) * 2019-06-18 2020-12-18 成都郑源生化科技有限公司 Method for preparing Fmoc-Tyr (tBu) -OH
CN112094204B (en) * 2019-06-18 2022-06-21 成都郑源生化科技有限公司 Method for preparing Fmoc-Tyr (tBu) -OH

Also Published As

Publication number Publication date
WO2014083575A3 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
US8604241B2 (en) Method for synthesis of (1S, 2R)-milnacipran
US20090143472A1 (en) Intermediate compounds and their use in preparation of lacosamide
KR20120128667A (en) A process for the preparation of lacosamide
KR101036536B1 (en) Synthesis of (S)-(+)-3- (aminomethyl) -5-methyl hexanoic acid
KR102122569B1 (en) Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1H-pyrazol-3-ylamine
WO2014125506A2 (en) A process for the preparation of ivacaftor and its intermediates
WO2014152752A1 (en) Methods for the synthesis of chiral kynurenine compounds
TW201806927A (en) Processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamides
WO2016024284A2 (en) A process for the preparation of mirabegron and its intermediates
CN115515957A (en) Stereoselective Synthesis of Intermediates for the Preparation of Heterocyclic Compounds
WO2014083575A2 (en) Improved process for the preparation of boceprevir intermediate
WO2013066734A1 (en) Process and intermediates for the preparation of 3-amino-4-cyclobutyl-2-hydroxybutanamide and salts thereof
WO2022241188A1 (en) Enantioselective synthesis of aminotropane compound
ZA200502275B (en) Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors
WO2011156355A1 (en) Production method of phenyl guanidine salts and their intermediates
US8957252B2 (en) Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives
JP5374895B2 (en) Process for producing optically active fluoroamines
JP2010090031A (en) Method of producing bicyclic proline compound
CN103249306A (en) Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium
JP6781030B2 (en) L-carnosine derivative or salt thereof, and method for producing L-carnosine or salt thereof
US10329325B2 (en) Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
RU2362766C2 (en) Method of obtaining benzylamine derivative and acylbenzylamine derivative
US20120101301A1 (en) Process for preparing carboxylic acid amides useful in the treatment of muscular disorders
US9718765B1 (en) Process for preparation of optically pure N-substituted-3-methoxypropionic acid derivatives
WO2007029267A1 (en) Process for industrially viable preparation of imidapril hydrochloride

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13821192

Country of ref document: EP

Kind code of ref document: A2